Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.

Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD.

Semin Oncol. 2001 Aug;28(4 Suppl 15):49-55.

PMID:
11685729
[PubMed - indexed for MEDLINE]
2.

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.

Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD.

J Clin Oncol. 2003 Jan 1;21(1):123-8.

PMID:
12506180
[PubMed - indexed for MEDLINE]
3.

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL.

Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6.

PMID:
11685731
[PubMed - indexed for MEDLINE]
4.

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.

Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA.

Cancer. 2002 Mar 1;94(5):1457-65.

PMID:
11920502
[PubMed - indexed for MEDLINE]
Free Article
5.

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.

Berry W, Dakhil S, Gregurich MA, Asmar L.

Semin Oncol. 2001 Aug;28(4 Suppl 15):8-15.

PMID:
11685723
[PubMed - indexed for MEDLINE]
6.

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators.

J Clin Oncol. 2007 Feb 20;25(6):669-74.

PMID:
17308271
[PubMed - indexed for MEDLINE]
Free Article
7.

ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.

Beer TM.

BJU Int. 2005 Sep;96(4):508-13.

PMID:
16104901
[PubMed - indexed for MEDLINE]
8.

Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.

Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G.

BJU Int. 2007 Oct;100(4):775-9. Epub 2007 May 29.

PMID:
17535276
[PubMed - indexed for MEDLINE]
9.

High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.

Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM.

J Urol. 2005 Sep;174(3):888-92.

PMID:
16093981
[PubMed - indexed for MEDLINE]
10.

Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.

Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.

Cancer. 2007 Sep 1;110(5):996-1002.

PMID:
17639587
[PubMed - indexed for MEDLINE]
Free Article
11.

Development of weekly high-dose calcitriol based therapy for prostate cancer.

Beer TM.

Urol Oncol. 2003 Sep-Oct;21(5):399-405. Review.

PMID:
14670552
[PubMed - indexed for MEDLINE]
12.

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD; ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators.

Cancer. 2008 Jan 15;112(2):326-30.

PMID:
17960793
[PubMed - indexed for MEDLINE]
Free Article
13.

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

Beer TM, Pierce WC, Lowe BA, Henner WD.

Ann Oncol. 2001 Sep;12(9):1273-9.

PMID:
11697840
[PubMed - indexed for MEDLINE]
Free Article
14.

Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.

Sitka Copur M, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, Norvell M, Muhvic J, Hake L, Wendt J.

Semin Oncol. 2001 Aug;28(4 Suppl 15):16-21.

PMID:
11685724
[PubMed - indexed for MEDLINE]
15.

A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.

Amato RJ, Sarao H.

Clin Genitourin Cancer. 2006 Mar;4(4):281-6.

PMID:
16729912
[PubMed - indexed for MEDLINE]
16.

Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.

Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ.

Intern Med J. 2005 Aug;35(8):468-72.

PMID:
16176469
[PubMed - indexed for MEDLINE]
17.

Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.

Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL.

Clin Pharmacol Ther. 2002 Dec;72(6):648-59.

PMID:
12496746
[PubMed - indexed for MEDLINE]
18.

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

Hainsworth JD, Burris HA 3rd, Erland JB, Thomas M, Greco FA.

J Clin Oncol. 1998 Jun;16(6):2164-8.

PMID:
9626217
[PubMed - indexed for MEDLINE]
19.

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR.

Cancer Biol Ther. 2002 Nov-Dec;1(6):646-51. Review.

PMID:
12642688
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

Dreicer R, Petrylak D, Agus D, Webb I, Roth B.

Clin Cancer Res. 2007 Feb 15;13(4):1208-15.

PMID:
17317831
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk